Niraparib needs to be taken for a long period of time and without special circumstances until the patient’s condition deteriorates or intolerable adverse reactions occur. It is mainly indicated for the maintenance treatment of adult patients with advanced fallopian tube, epithelial ovarian or primary peritoneal cancer after achieving complete remission or partial remission on first-line platinum-containing chemotherapy. This product needs to be administered all the time and can effectively prolong the survival of patients. Discontinuation should be considered only if the patient’s disease progresses or if intolerable adverse reactions occur. The most frequent adverse reactions to this product include myelosuppression, nausea, abdominal pain, vomiting, anemia, fatigue, constipation, loss of appetite, insomnia, headache, etc. Therefore, complete blood counts should be rechecked regularly, and it is contraindicated for those who are allergic to this product. Please follow the doctor’s instructions to adhere to the medication, do not stop the drug. Please consult your physician if any significant discomfort occurs.